Patent opinions from the Eastern District of Texas and the U.S. Court of Appeals for the Federal Circuit

Weekly Digest
Fed. Cir.

Luitpold Pharmaceuticals, Inc. v. Pharmacosmos A/S, No. 17-1786 (Fed. Cir. Apr. 12, 2018)

Dismissed
Court
U.S. Court of Appeals for the Federal Circuit
Case No.
No. 17-1786
Decided
April 12, 2018
Judge
Per curiam
Document
Nonprecedential Opinion
Length
2 pages

NOTE: This order is nonprecedential. United States Court of Appeals

for the Federal Circuit LUITPOLD PHARMACEUTICALS, INC.,

Appellant

v.

PHARMACOSMOS A/S,

Cross-Appellant

2017-1786

Appeal from the United States Patent and Trademark Office, Patent Trial and Appeal Board in No. IPR2015-01490.

O R D E R

Before PROST, Chief Judge, WALLACH and TARANTO,

Circuit Judges.

Pharmacosmos A/S cross-appeals from the Patent Trial and Appeal Board’s Final Written Decision determining that it did not prove by a preponderance of the evidence that claims 17 and 47 of U.S. Patent No. 7,754,702 are unpatentable. Because Pharmacosmos has not established an injury in fact sufficient to confer Arti-22 LUITPOLD PHARMACEUTICALS, INC. v. PHARMACOSMOS A/S

cle III standing, however, this court dismisses the cross-appeal. IT IS ORDERED THAT:

This case is dismissed. FOR THE COURT

April 12, 2018 /s/ Peter R. Marksteiner Date Peter R. Marksteiner Clerk of Court

Text extracted from the official PDF and reflowed for reading. It is not a certified transcript — the PDF linked above is the authoritative document.

Analysis is coming soon.

A plain-English account of the issues, facts and holding, written by Patent Case Watch. The opinion itself — its full text, its PDF and everything else on this page — stays free to read for everyone, always.

Cite this opinion

Luitpold Pharmaceuticals, Inc. v. Pharmacosmos A/S, No. 17-1786 (Fed. Cir. Apr. 12, 2018).

Record ID
CAFC-17-1786-20180412
Permalink
https://patentcasewatch.com/opinions/CAFC-17-1786-20180412

No reporter citation is shown because the official source does not supply one; none is inferred here. Check the opinion and a citator before relying on this form.